daxibotulinumtoxinA

New neurotoxin on the block starts phase 3 trialsThe injectable neurotoxin drug candidate daxibotulinumtoxinA for injection (RT002, Revance Therapeutics) started phase 3 SAKURA trials in December 2016
Revance injectable outperforms BotoxAccording to early research, not-yet-approved RT002 (DaxibotulinumtoxinA for Injection, Revance Therapeutics) lasts longer, might be safer and offers more dramatic wrinkle reduction than today’s most popular neurotoxin Botox (Allergan).